Evidence map›Paper›PMID 31669083›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2020

Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo.

Sushant Lakkadwala, Bruna Dos Santos Rodrigues, Chengwen Sun, Jagdish Singh

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sushant LakkadwalaDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA.
Bruna Dos Santos RodriguesDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA.
Chengwen SunDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA.
Jagdish SinghDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA. Electronic address: jagdish.singh@ndsu.edu.
North Dakota State University · US

Funding

Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimer’s DiseaseR01AG051574 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2016 to 2020
$2.0M
NIA NIH HHS R01 AG051574
6 · The paper itself

Abstract

Combination therapy has emerged as an efficient way to deliver chemotherapeutics for treatment of glioblastoma. It provides collaborative approach of targeting cancer cells by acting via multiple mechanisms, thereby reducing drug resistance. However, the presence of impermeable blood brain barrier (BBB) restricts the delivery of chemotherapeutic drugs into the brain. To overcome this limitation, we designed a dual functionalized liposomes by modifying their surface with transferrin (Tf) and a cell penetrating peptide (CPP) for receptor and adsorptive mediated transcytosis, respectively. In this study, we used two different CPPs (based on physicochemical properties) and investigated the influence of insertion of CPP to Tf-liposomes on biocompatibility, cellular uptake, and transport across the BBB both in vitro and in vivo. The biodistribution profile of Tf-CPP liposomes showed more than 10 and 2.7 fold increase in doxorubicin and erlotinib accumulation in mice brain, respectively as compared to free drugs with no signs of toxicity.

Indexed as

Antineoplastic AgentsCell-Penetrating PeptidesDoxorubicinDrug Delivery SystemsErlotinib HydrochlorideTransferrinAnimalsBlood-Brain BarrierFemaleLiposomesMaleMiceMice, NudeAntineoplastic AgentsCell-Penetrating PeptidesDoxorubicinErlotinib HydrochlorideLiposomesTransferrinBiodistributionCombination therapyDual functionalized liposomesGlioblastomaIn vitro brain tumor model

Identifiers

PMID31669083
PMCPMC6935563
OpenAlexW2981820762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.